Abiopharma

🔍 Cain Wettan Keeley M (Executive)

Company: GILEAD SCIENCES, INC. (GILD)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 1,246 shares of Common Stock (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,660.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 606 shares of Common Stock at $148.56 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 5,054.00 | transaction_form_type: 4
• Sold 1,246 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,536.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2
• Acquired 5,050 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 20,586.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2
• Acquired 18,885 shares of Non-qualified Stock Option (Right to Buy) at $148.56 per share (Derivative)
  Date: 2026-03-10 | Code: A | Expires: 2036-03-10 | equity_swap_involved: 0 | shares_owned_after: 18,885.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
• F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
• F3: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.